Research Review
Role of dopamine transporter imaging in routine clinical practice
Vicky Marshall MRCP,
Donald Grosset BSc, MD,
Corresponding Author
Vicky Marshall MRCP
Institute of Neurological Sciences, Glasgow, United Kingdom
Institute of Neurological Sciences, Southern General Hospital, 1345 Govan Road, Glasgow G51 4TF, United KingdomSearch for more papers by this authorDonald Grosset BSc, MD
Institute of Neurological Sciences, Glasgow, United Kingdom
Search for more papers by this authorVicky Marshall MRCP,
Donald Grosset BSc, MD,
Corresponding Author
Vicky Marshall MRCP
Institute of Neurological Sciences, Glasgow, United Kingdom
Institute of Neurological Sciences, Southern General Hospital, 1345 Govan Road, Glasgow G51 4TF, United KingdomSearch for more papers by this authorDonald Grosset BSc, MD
Institute of Neurological Sciences, Glasgow, United Kingdom
Search for more papers by this authorAbstract
Functional imaging of the dopamine transporter (DAT) defines integrity of the dopaminergic system and has its main clinical application in patients with mild, incomplete, or uncertain parkinsonism. Imaging with specific single positron emission computerised tomography ligands for DAT (FP-CIT, β-CIT, IPT, TRODAT) provides a marker for presynaptic neuronal degeneration. Striatal uptake correlates with disease severity, in particular bradykinesia and rigidity, and monitoring of progression assists in clinical trials of potential neuroprotective drugs. DAT imaging is abnormal in idiopathic Parkinson's disease, multiple system atrophy and progressive supranuclear palsy and does not distinguish between these disorders. Dopamine loss is seen even in the earliest clinical presentations of true parkinsonism; a normal scan suggests an alternative diagnosis such as essential tremor, vascular parkinsonism (unless there is focal basal ganglia infarction), drug-induced parkinsonism, or psychogenic parkinsonism. Congruence between working clinical diagnosis and DAT imaging increases over time in favour of baseline DAT imaging results. Additional applications are characterising dementia with parkinsonian features (abnormal results in dementia with Lewy bodies, normal in Alzheimer's disease); and differentiating juvenile-onset Parkinson's disease (abnormal DAT) from dopa-responsive dystonia (normal DAT). © 2003 Movement Disorder Society
REFERENCES
- 1
Hughes AJ,
Daniel SE,
Kilford L, et al.
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.
J Neurol Neurosurg Psychiatry
1992;
55:
181–184.
- 2
Fearnley JM
Lees AJ.
Striatonigral degeneration. A clinicopathological study.
Brain
1990;
113 (Pt
6):
1823–1842.
- 3
Hughes AJ,
Ben Shlomo Y,
Daniel SE, et al.
What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study.
Neurology
2001;
57:
S34–S38.
- 4
Hughes AJ,
Daniel SE,
Ben Shlomo Y, et al.
The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service.
Brain
2002;
125:
861–870.
- 5
Meara J,
Bhowmick BK,
Hobson P.
Accuracy of diagnosis in patients with presumed Parkinson's disease.
Age Ageing
1999;
28:
99–102.
- 6
Wilson JM,
Levey AI,
Rajput A, et al.
Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease.
Neurology
1996;
47:
718–726.
- 7
Kaufman MJ
Madras BK.
Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum.
Synapse
1991;
9:
43–49.
- 8
Niznik HB,
Fogel EF,
Fassos FF, et al.
The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus.
J Neurochem
1991;
56:
192–198.
- 9
Jaber M,
Jones S,
Giros B, et al.
The dopamine transporter: a crucial component regulating dopamine transmission.
Mov Disord
1997;
12:
629–633.
- 10
Mozley PD,
Schneider JS,
Acton PD, et al.
Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers.
J Nucl Med
2000;
41:
584–589.
- 11
Marek K,
Innis RB,
Van Dyck CH, et al.
[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.
Neurology
2001;
57:
2089–2094.
- 12
Kim HJ,
Im JH,
Yang SO, et al.
Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects.
J Nucl Med
1997;
38:
1703–1711.
- 13
Booij J,
Tissingh G,
Boer GJ, et al.
[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
J Neurol Neurosurg Psychiatry
1997;
62:
133–140.
- 14
Abi-Dargham A,
Gandelman MS,
DeErausquin GA, et al.
SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT.
J Nucl Med
1996;
37:
1129–1133.
- 15
Kao P-F,
Tzen K-Y,
Yen T-C, et al.
The optimal imaging time for [99mTc]TRODAT-1/SPET in normal subjects and patients with Parkinson's disease.
Nucl Med Commun
2001;
22:
151–154.
- 16
Booij J,
Tissingh G,
Winogrodzka A, et al.
Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease.
Eur J Nucl Med
1997;
24:
68–71.
- 17
Booij J,
Habraken JB,
Bergmans P, et al.
Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
J Nucl Med
1998;
39:
1879–1884.
- 18
Seibyl JP,
Marek K,
Sheff K, et al.
Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
J Nucl Med
1997;
38:
1453–1459.
- 19
Innis RB,
Marek K,
Sheff K, et al.
Effect of treatment with l-dopa/carbidopa or l-selegiline on striatal dopamine transporter SPECT imaging with [123 I] beta-CIT.
Mov Disord
1999;
14:
436–442.
- 20
Marek K,
Seibyl J,
Shoulson I, et al.
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
JAMA
2002;
287:
1653–1661.
- 21
Ahlskog JE,
Uitti RJ,
O'Connor MK, et al.
The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease.
Mov Disord
1999;
14:
940–946.
- 22
Lee CS,
Samii A,
Sossi V, et al.
In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
Ann Neurol
2000;
47:
493–503.
- 23
Haapaniemi TH,
Ahonen A,
Torniainen P, et al.
[123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients.
Mov Disord
2001;
16:
124–130.
- 24
Tissingh G,
Bergmans P,
Booij J, et al.
Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT.
J Neurol
1998;
245:
14–20.
- 25
Marek K,
Seibyl J,
Zoghbi SS, et al.
[123I]beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease.
Neurology
1996;
46:
231–237.
- 26
Berendse HW,
Booij J,
Francot CM, et al.
Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell.
Ann Neurol
2001;
50:
34–41.
- 27
Benamer HT,
Patterson J,
Wyper DJ, et al.
Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake.
Mov Disord
2000;
15:
692–698.
- 28
Seibyl JP,
Marek KL,
Quinlan D, et al.
Decreased single-photon emission computed tomographic [123 I]&rtf-space;β-CIT striatal uptake correlates with symptom severity in Parkinson's disease.
Ann Neurol
1995;
38:
589–598.
- 29
Lavalaye J,
Booij J,
Reneman L, et al.
Effect of age and gender on dopamine transporter imaging with [123 I] FP-CIT SPET in healthy volunteers.
Eur J Nucl Med
2000;
27:
867–869.
- 30
Van Dyck CH,
Seibyl JP,
Malison RT, et al.
Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT.
J Nucl Med
1995;
36:
1175–1181.
- 31
Winogrodzka A,
Bergmans P,
Booij J, et al.
[123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease.
J Neural Transm
2001;
108:
1011–1019.
- 32
Pirker W,
Djamshidian S,
Asenbaum S, et al.
Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study.
Mov Disord
2002;
17:
45–53.
- 33
Asenbaum S,
Pirker W,
Angelberger P, et al.
[123I]beta-CIT and SPECT in essential tremor and Parkinson's disease.
J Neural Transm
1998;
105:
1213–1228.
- 34
Benamer TS,
Patterson J,
Grosset DG, et al.
Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group.
Mov Disord
2000;
15:
503–510.
- 35
Marek K,
Seibyl J,
Holloway R, et al.
A multicentre assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism.
Neurology
2000;
55:
1540–1547.
- 36
Rajput AH,
Rozdilsky B,
Ang L, et al.
Clinicopathologic observations in essential tremor: report of six cases.
Neurology
1991;
41:
1422–1424.
- 37
Marek K.
Pramipexole versus Levodopa in the CALM-PD CIT study: effects on Parkinson's disease progression assessed by dopamine transporter imaging.
Parkinson Study Group. Presentation EFNS Vienna
2002.
- 38
Fahn S.
Results of the ELLDOPA (earlier vs. later levodopa) study. Presentation at Seventh International Congress of Parkinson's Disease and Movement Disorders, Miami, Florida
2002.
- 39
Jennings D,
Seibyl J,
Marek K.
β-CIT SPECT versus clinical examination in parkinsonian syndrome: unmasking and early diagnosis [abstract].
Mov Disord
2002;
17:
1108.
- 40
Lee MS,
Kim YD,
Im JH, et al.
123I-IPT brain SPECT study in essential tremor and Parkinson's disease.
Neurology
1999;
52:
1422–1426.
- 41
Booij J,
Speelman JD,
Horstink MW, et al.
The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism.
Eur J Nucl Med
2001;
28:
266–272.
- 42
Brucke T,
Asenbaum S,
Pirker W, et al.
Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
J Neural Transm Suppl
1997;
50:
9–24.
- 43
Varrone A,
Marek KL,
Jennings D, et al.
[123 I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy.
Mov Disord
2001;
16:
1023–1032.
- 44
Pirker W,
Asenbaum S,
Bencsits G, et al.
[123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration.
Mov Disord
2000;
15:
1158–1167.
- 45
Kim YJ,
Ichise M,
Ballinger JR, et al.
Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.
Mov Disord
2002;
17:
303–312.
- 46
Dresel SH,
Kung MP,
Huang XF, et al.
Simultaneous SPECT studies of pre- and postsynaptic dopamine binding sites in baboons.
J Nucl Med
1999;
40:
660–666.
- 47
Winikates J
Jankovic J.
Clinical correlates of vascular parkinsonism.
Arch Neurol
1999;
56:
98–102.
- 48
Daniel SE
Lees AJ.
Parkinson's Disease Society Brain Bank, London: overview and research.
J Neural Transm
Suppl
1993;
39:
165–172.
- 49
Tzen KY,
Lu CS,
Yen TC, et al.
Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1.
J Nucl Med
2001;
42:
408–413.
- 50
Gerschlager W,
Bencsits G,
Pirker W, et al.
[123I]B-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease.
Mov Disord
2002; 17: 518–523.
- 51
Stevens T,
Livingston G,
Kitchen G, et al.
Islington study of dementia subtypes in the community.
Br J Psychiatry
2002;
180:
270–276.
- 52
McKeith IG,
Fairbairn AF,
Perry RH, et al.
The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT).
Br J Psychiatry
1994;
165:
324–332.
- 53
Ala TA,
Yang KH,
Sung JH, et al.
Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at presentation: a clinicopathological study.
J Neurol Neurosurg Psychiatry
1997;
62:
16–21.
- 54
Swanberg MM
Cummings JL.
Benefit-risk considerations in the treatment of dementia with Lewy bodies.
Drug Safety
2002;
25:
511–523.
- 55
Ditter SM
Mirra SS.
Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients.
Neurology
1987;
37:
754–760.
- 56
Hansen L,
Salmon D,
Galasko D, et al.
The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity.
Neurology
1990;
40:
1–8.
- 57
McKeith IGM,
Galasko DM,
Kosaka KM, et al.
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.
Neurology
1996;
47:
1113–1124.
- 58
McKeith IGM,
Ballard CGM,
Perry RHM, et al.
Prospective validation of Consensus criteria for the diagnosis of dementia with Lewy bodies.
Neurology
2000;
54:
1050–1058.
- 59
Bowler JV,
Munoz DG,
Merskey H, et al.
Fallacies in the pathological confirmation of the diagnosis of Alzheimer's disease.
J Neurol Neurosurg Psychiatry
1998;
64:
18–24.
- 60
Piggott MA,
Marshall EF,
Thomas N, et al.
Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
Brain
1999;
122:
1449–1468.
- 61
Walker Z,
Costa DC,
Walker RW, et al.
Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand.
J Neurol Neurosurg Psychiatry
2002;
73:
134–140.
- 62
Donnemiller E,
Heilmann J,
Wenning GK, et al.
Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease.
Eur J Nucl Med
1997;
24:
320–325.
- 63
Rinne JO,
Laine M,
Kaasinen V, et al.
Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia.
Neurology
2002;
58:
1489–1493.
- 64
Rajput AH,
Offord KP,
Beard CM, et al.
Epidemiology of parkinsonism: incidence, classification, and mortality.
Ann Neurol
1984;
16:
278–282.
- 65
Montastruc JL,
Llau ME,
Rascol O, et al.
Drug-induced parkinsonism: a review.
Fundam Clin Pharmacol
1994;
8:
293–306.
- 66
Stephen PJ
Williamson J.
Drug-induced parkinsonism in the elderly.
Lancet
1984;
2:
1082–1083.
- 67
Caligiuri MP,
Lacro JP,
Jeste DV.
Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics.
J Clin Psychopharmacol
1999;
19:
322–328.
- 68
Masso MJF,
Carrera N,
Urtasun M, et al.
Drugs inducing parkinsonism in our environment.
J Neurol Neurosurg Psychiatry
1991;
54:
1025.
- 69
Rajput AH,
Rozdilsky B,
Hornykiewicz O, et al.
Reversible drug-induced parkinsonism. Clinicopathologic study of two cases.
Arch Neurol
1982;
39:
644–646.
- 70
Chabolla DR,
Maraganore DM,
Ahlskog JE, et al.
Drug-induced parkinsonism as a risk factor for Parkinson's disease: a historical cohort study in Olmsted County, Minnesota.
Mayo Clin Proc
1998;
73:
724–727.
- 71
Friedman JH,
Jennings D,
Seibyl J, et al.
β-CIT SPECT Imaging to distinguish drug-induced parkinsonism from idiopathic Parkinson's disease exacerbated by drugs: pilot data. Part 1.
Mov Disord
2002;
17:
1108.
- 72
Lavalaye J,
Linszen DH,
Booij J, et al.
Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT.
Schizophr Res
2001;
47:
59–67.
- 73
Booij J,
Rijk-van Andel PJ,
Noorden RA.
No loss of striatal dopamine transporters and D2 receptors in patients with autosomal recessive dopa-responsive dystonia.
J Nucl Med
1999;
40:
67.
- 74
Jeon BS,
Jeong JM,
Park SS, et al.
Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
Ann Neurol
1998;
43:
792–800.
- 75
Naumann M,
Pirker W,
Reiners K, et al.
[123I]beta-CIT single-photon emission tomography in DOPA-responsive dystonia.
Mov Disord
1997;
12:
448–451.
- 76
Koller WC,
Lang A,
Vetere-Overfield RN, et al.
Psychogenic tremors.
Neurology
1989;
39:
1094–1099.
- 77
O'Sullivan JD,
Costa DC,
Lees AJ.
Confirming Parkinson's disease with 123I FP-CIT SPECT (abstract).
Eur J Neurol
1999;
6:
131.
- 78
Jeon B,
Kim JM,
Jeong JM, et al.
Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease.
J Neurol Neurosurg Psychiatry
1998;
65:
60–64.
- 79
Yen TC,
Lu CS,
Tzen KY, et al.
Decreased dopamine transporter binding in Machado-Joseph disease.
J Nucl Med
2000;
41:
994–998.
- 80
Borasio GD,
Linke R,
Schwarz J, et al.
Dopaminergic deficit in amyotrophic lateral sclerosis assessed with [I-123] IPT single photon emission computed tomography.
J Neurol Neurosurg Psychiatry
1998;
65:
263–265.
- 81
Malison RT,
McDougle CJ,
Van Dyck CH, et al.
[123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder.
Am J Psychiatry
1995;
152:
1359–1361.
- 82
Naumann M,
Pirker W,
Reiners K, et al.
Imaging the pre- and postsynaptic side of striatal dopaminergic synapses in idiopathic cervical dystonia: a SPECT study using [123I] epidepride and [123I] beta-CIT.
Mov Disord
1998;
13:
319–323.
- 83
Tolosa E
Catafau AM.
Clinical Impact of performing SPECT imaging with the dopamine transporter imaging agent 123 I-ioflupane (DaTSCAN) in patients with a clinically uncertain diagnosis of parkinsonian syndromes (abstract).
Eur J Neurol
2002;
9:
27.
- 84
Løkkegaard A,
Werdelin LM,
Friberg L.
Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand.
Eur J Nucl Med
2002;
29:
1623-1629.
